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Background: Alexithymia frequently correlates with several psychiatric disorders,
including substance use disorder (SUD). However, most studies reporting the
associations between alexithymia and psychiatric disorders have been performed in
populations without SUD. This research, therefore, evaluates alexithymia in Spanish
patients with SUD and the relationship among alexithymia, psychiatric comorbidities,
psychological symptoms/traits, SUD variables, and health-related quality of life (HRQoL).
Methodology: A cross-sectional study was conducted with 126 Spanish outpatients
with SUD (75.4% males; mean age 43.72 ± 14.61 years), correlating their alexithymia
levels (using the Toronto Alexithymia Scale 20 [TAS-20]) to their psychiatric comorbidities,
psychological symptoms/traits, SUD variables, and HRQoL.
Results: Alexithymia was significantly higher in patients who had cannabis use disorder.
Higher alexithymia scores were also related to higher levels of depression, anxiety,
impulsivity, and lower HRQoL. After multivariate analysis, trait anxiety, impulsivity, and
the physical component summary of the HRQoL were found to be independently related
to alexithymia.
Conclusions: SUD patients with higher alexithymia levels have more frequently
psychiatric comorbidities, present specific psychological features, and have worse
HRQoL. Hence, it is important to evaluate these factors and offer more accurate
psychotherapeutic approaches for this patient population.
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INTRODUCTION
Substance use disorder (SUD) is a complex, multifactorial,
and chronic disease that negatively influences on health, social
and economic status (1, 2). Several mechanisms are implicated
in SUD pathogenesis, particularly emotional regulation issues,
from both biological and clinical viewpoints (3–5). Alexithymia
is a multidimensional construct, and it is a key point in
emotional processes, as emotional awareness and identification
are critical to regulating emotions (4, 6–8). Alexithymia involves
four main dimensions: difficulty identifying and/or describing
feelings, difficulty differentiating feelings from bodily sensations,
a decrease in or absence of symbolic thinking, and an externally
oriented cognitive style (9, 10). When analyzed as a categorical
trait, in the general population, the prevalence of alexithymia
is estimated to be 6–10%, and, in SUD patients, it is estimated
to be 42–67% (7, 11–13). However, despite some controversies
about whether alexithymia should be considered a categorical
or dimensional variable, the current literature states that it is
a normally distributed trait in the population, with a relative
stability across the lifespan (8, 9, 14, 15). Alexithymia also
seems to be a stable trait, independent of substance use or
withdrawal (7, 16), although not all research supports this point
(17). Some studies suggest that alexithymia is related to risky
substance use (18, 19), more severe addictions (20), higher
craving levels (21), and more treatment dropouts/relapses (7).
Additionally, alexithymia seems to be related to family history
of alcohol dependence (22). Finally, it is important to note
that alexithymia may interfere with treatment aims, especially
in emotional and insight-oriented therapies (11, 23, 24). SUD
patients with higher alexithymia levels may have more problems
in engaging psychotherapeutic treatments and would form
weaker therapeutic alliances (24, 25). However, not all researchers
conclude that alexithymia is related to SUD outcomes (5, 7, 26),
and hence, it is important to conduct more research on this issue.
Alexithymia is frequently related to psychiatric disorders,
including SUD, psychosis, anxiety, and depressive disorders
(10, 27, 28). Most studies reporting associations between
alexithymia and psychiatric disorders have been performed in
populations without SUD, even though psychiatric comorbidities
are frequently observed in SUD patients (1, 23, 24, 27, 28).
Nonetheless, as in the studies performed in populations without
SUD, the limited clinical research that is available states that
alexithymia may be related to several psychiatric disorders
in SUD patients (11, 19, 29, 30). In any case, the role of
alexithymia in SUD is not well-established, especially regarding
how comorbidities are related to SUD in those patients with
alexithymia (7). On one hand, some authors argues that
alexithymia may partially predict the presence of anxiety and
depression in alcohol-dependent patients (7, 30). On the other
hand, other authors propose that depression could lead to alcohol
dependence in patients with alexithymia (31). Personality traits
and disorders have also been associated with higher levels of
alexithymia in SUD patients (32), and the relationship between
alexithymia and primary psychotic disorders (e.g., schizophrenia)
is relatively well-documented (33). It has been proposed that
alexithymia may predict psychotic experiences or be a risk factor
for psychosis (28, 34). Nevertheless, as far as we know, no
specific study has been conducted concerning alexithymia in
SUD patients with schizophrenia or other psychotic disorders.
However, it could be expected that alexithymia is related to
psychotic disorders in SUD patients, as it has already been
associated with cannabis or other substance use (7, 29) and as
substance use is a risk factor for primary psychotic disorders
and substance-induced psychosis (35). In any case, as highlighted
above, no specific manuscript on this issue has been published.
A negative association has been reported between alexithymia
and health-related quality of life (HRQoL) in general and clinical
populations (36–38). However, this relationship has been scarcely
studied in the addiction field, as only two studies have been
designed for this purpose. It is, therefore, generally believed
that, in SUD patients, as in patients with other disorders, lower
alexithymia levels mean better HRQoL (36, 38).
Finally, the association between alexithymia and psychiatric
comorbidities in SUD patients has been scarcely studied in the
Spanish population. Most research in this group has considered
alexithymia with other psychiatric disorders, examined substance
consumption as a secondary variable, or included patients with
long periods of abstinence from substance use (39, 40). Also, to
our knowledge, no studies on the relationship between HRQoL
and alexithymia have been performed in Spanish SUD patients.
This point has a crucial importance as alexithymia is a valid cross-
cultural construct but with level differences among cultures (8),
and hence, comparisons on this issue among different cultures
shed light on understanding alexithymia in clinical practice.
Therefore, this study evaluates alexithymia in Spanish SUD
outpatients and the relationship among alexithymia, psychiatric
comorbidities, psychological symptoms/traits, SUD variables,
and HRQoL. We hypothesize that SUD patients with higher
alexithymia levels will exhibit more psychiatric comorbidities,
more anxiety and depression, and worse HRQoL values.
METHODS
A cross-sectional study was conducted in an outpatient addiction
treatment center in Barcelona, Spain. SUD patients who sought
treatment between January 2018 and January 2019 were included.
This study was approved by the Hospital Ethics Committee
according to the World Medical Association’s Declaration of
Helsinki. Sampled patients received no financial compensation
for participating.
To be included in the study, patients were required to: be
over 18 years of age, have Spanish nationality, meet SUD criteria
according to the Diagnostic and Statistical Manual of Mental
Disorders Fifth Edition (DSM-5) (41), be actively consuming
substances, and understand and sign the written informed
consent document prior to participation. Patients were excluded
if they were cognitively impaired, were acutely intoxicated,
presented language barriers, or were currently involved in a
pharmacological clinical trial. Note that cognitive impairment
was evaluated by two ways: the first one by assessing the
clinical history of any cognitive impairments, and the second
one by clinical assessment and by using Mini-Mental State
Examination (≥27). Therefore, participants with previous history
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of cognitive impairment or with a cognitive impairment detected
at the first visit were excluded. Patients who were acutely
intoxicated during their first appointment were invited to
participate in the second meeting. Regarding language barriers,
and according to study aims, all patients had to speak Spanish
since validated instruments in their Spanish version were used
(see below).
The evaluation process consisted of four visits conducted
by trained staff (psychiatrists and psychologists) during each
patient’s 1st week at the outpatient center, concurrent with the
usual outpatient treatment.
Measures
- Sociodemographic, medical, psychiatric, and addiction-related
variables: An ad-hoc questionnaire was developed to gather
and systematize the patients’ sociodemographic characteristics
and their medical, psychiatric, and addiction-related variables.
- Psychiatric comorbidities: The Semi-Structured Clinical
Interview for Axis-I Disorders of the DSM-IV (SCID-I) and
the Semi-Structured Clinical Interview for Axis-II Disorders
of the DSM-IV (SCID-II) were used to assess patients’
psychiatric comorbidities (42).
- Addiction severity: The European Addiction Severity Index
(EuropASI) was employed to evaluate addiction severity, as it
considers general consumption variables, legal problems, and
family/social relationships, as well as medical, occupational,
psychological, and economic status (43, 44). The median for
each component was used for the analysis.
- Beck Depression Inventory (BDI-I): This self-reported rating
inventory measures depression symptomatology (45, 46).
It classifies depression, according to points, as follows: no
depression (or normal mood): 1–10 points; mild mood
disturbance: 11–16 points; borderline clinical depression:
17–20 points; moderate depression: 21–30 points; severe
depression: 31–40 points; and extreme depression: more than
40 points (45, 46). For analysis in this research, we grouped
the scores into patients with 1–16 points and those with 17+,
because, from 17 onwards, the score is clinically relevant.
- State-Trait Anxiety Inventory (STAI): This inventory is
commonly used in clinical settings to measure anxiety (trait
and state) (47).
- Health-related quality of life (HRQoL): The 36-Item Short
Form Health Survey (SF-36) was used to measure functional
health and well-being from the patients’ perspectives (48). The
SF-36 provides scores for eight domains (physical functioning,
role limitations due to physical problems, bodily pain, general
health perceptions, vitality, social functioning, role limitations
due to emotional problems, and mental health), which can
be aggregated into two summary measures: the physical
component summary (PCS) and the mental component
summary (MCS). We used a cutoff value of 50 points, because,
from this score onward, patients exhibit better HRQoL.
- Barratt Impulsivity Scale (BIS-11): This self-reported scale
measures “trait impulsivity” and provides a total score and
three subscale scores: cognitive impulsivity, motor impulsivity,
and unplanned impulsivity (49).
- The Dickman Impulsivity Inventory (DII): This 23-item, self-
reported instrument evaluates functional and dysfunctional
impulsivity (50).
- Toronto Alexithymia Scale 20 (TAS-20): This self-reported
instrument is considered the “gold standard” for alexithymia
evaluation, and it has demonstrated its reliability and validity
in several cultures and languages (8, 9, 14, 51). The TAS-
20 measures alexithymia across 20 items, rated from one
to five. The sum of the ratings for those items generates
a total score, and the higher the score, the higher the
level of alexithymia. This scale has three subscales: difficulty
in identifying feelings, difficulty in describing feelings, and
externally oriented cognition (14, 51). The TAS-20 was not
developed to independently assess these three subscales but to
consider them together, as a single measure (14). Some authors
analyze alexithymia as a dichotomous variable (alexithymia vs.
non-alexithymia) and use 61 points as cutoff value for this
scale, but other researches recommend analyzing alexithymia
as a dimensional or spectrum trait (8, 9, 14). Therefore,
we decided to analyze each patient’s total TAS-20 score
(dimensional) and compare it to the other variables included
in the research.
Statistical Analyses
Descriptive, bivariate and multivariate analyses were performed.
The descriptive analysis involved measuring percentages, means,
medians, and standard deviations. The bivariate analysis
was subsequently performed using Student’s t-test, with the
alexithymia score being evaluated for each variable. To
dichotomize some variables, we chose generally accepted cutoff
points. Thus, the cutoff point for the BDI was 17 points or
more, as scores >17 are clinically relevant for depression (45,
46), and the cutoff value for the SF-36 was set to 50 points
because, from 50 onward, patients exhibit better HRQoL. For the
EuropASI, STAI, BIS-11, and DII measures, we chose themedian.
Bonferroni correction was executed to reduce false positives.
Finally, a multivariate analysis (linear regression) was performed
via a stepwise method, including variables that retained statistical
significance after the Bonferroni correction. All statistical tests
were two-sided, and a value of p < 0.05 was considered
statistically significant. SPSS version 21 statistical software was
employed in this project.
RESULTS
During the recruitment period, 204 patients began a new
treatment process, but 78 were excluded for the following
reasons: no active substance consumption (n = 26), language
barriers (n = 21), and not agreeing to participate (n = 31).
Therefore, 126 patients met the inclusion criteria. Among these,
the mean age was 43.72 ± 14.61 years old (median 40), and
the sample contained 94 men (75.4%). The participants’ mean
TAS-20 score was 57.40 ± SD 12.98, and the prevalence of
alexithymia was 41.3% (using 61 points as cutoff). No gendered
differences were found. Regarding sociodemographic variables,
only coexistence and academic level were significantly related to
higher alexithymia levels (Table 1).
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TABLE 1 | Sociodemographic variables related to alexithymia levels.
Variable % Mean score of TAS-20 ± SD t p
Age (years)
(mean: 43.72 ± 14.61;
median: 40)
<40 50 59.27 ± 13.24 1.773 0.079
≥40 50 55.52 ± 12.16
Sex
Males 75.4 56.80 ± 13.0 0.851 0.396
Females 24.6 59.10 ± 12.95
Marital status
Married 40.7 56.50 ± 12.34 0.254 0.800
Other 59.3 57.11 ± 13.30
Coexistence
Family 66.1 54.54 ± 11.59 2.128 <0.037*
Other 33.9 60.26 ± 14.34
Level of studies
<8 years 86.8 57.62 ± 13.27 2.007 <0.047*
≥8 years 13.2 50.53 ± 8.08
Criminal records
Yes 38.1 55.95 ± 12.90 0.306 0.760
No 61.9 56.77 ± 13.57
*The result is statistically significant.
Regarding substance use variables (Table 2), participants most
often used alcohol (excluding tobacco), followed by cocaine and
cannabis. Alexithymia levels were significantly higher in patients
who had a history of cannabis use disorder. There were also
correlations between TAS-20 and worse EuropASI scores for the
family/social and psychological items.
Regarding psychiatric comorbidities and psychological
variables (Table 3), SUD patients with psychiatric comorbidities
had higher alexithymia levels, especially those affected by
the mood disorder spectrum and the psychotic disorder
spectrum (clearly in substance-induced psychosis). Also,
some psychological traits were associated with higher
alexithymia scores, specifically depression (BDI), anxiety
(STAI), and impulsivity (BIS-11; DII). Patients with higher
TAS-20 scores had worse HRQoL scores, with a statistical
significance in all domains and component summaries (PCS
and MCS).
A multivariate analysis was performed using the variables
that retained statistical significance after Bonferroni correction.
The following variables were included in the linear regression:
lifetime history of cannabis use disorder, EuropASI psychological
domain, substance-induced psychosis, BDI, STAI, BIS-11 total
score, DII dysfunctional impulsivity, and PCS and MCS
values from the SF-36. The linear regression (R2 = 0.397;
F = 10.296; p < 0.001) showed that trait anxiety according
to STAI (Beta 2.740; t = 2.895; p = 0.006), BIS-11 total
score (Beta 3.745; t = 2.248; p = 0.029), and PCS (Beta
3.861; t = 2.147; p = 0.037) were independently related
to alexithymia.
DISCUSSION
The current research provides new information on alexithymia in
SUD patients, especially on the relationship among alexithymia,
psychiatric comorbidities, and psychological characteristics. We
found that SUD patients with cannabis use disorder, psychiatric
comorbidities (especially mood and psychotic spectrum
disorders), impulsivity, anxiety, or depressive symptoms have
higher alexithymia levels. These higher alexithymia levels were
also related to worse HRQoL scores (particularly on PCS) in SUD
patients. The prevalence of alexithymia and the TAS-20 mean
score found in this research were similar to those determined in
previous studies among SUD patients (7, 13, 21, 22) and were
higher compared to general populations (7, 12).
Regarding current results, cannabis use disorder and
anxiety (particularly trait anxiety in the multivariate analysis)
were significantly related to higher alexithymia levels. These
associations may be explained in several ways and the causality
association is beyond the current study due to the cross-
sectional design. One explanation is that those associations
are independent, specifically that the mere trait anxiety
(independently of alexithymia) may be one of the most
important predictors of cannabis use disorder (29). Another
explanation is that both alexithymia and anxiety could lead to
substance use as a self-medication strategy for managing distress
(7, 52). In this vein, Dorard et al. (29) propose that patients with
alexithymia and anxiety may use cannabis as a stress-coping
strategy (29). Finally, it has been described that alexithymia and
SUD severity are important anxiety predictors (30). For all the
above, the current findings should be analyzed in longitudinal
studies to evaluate better how alexithymia, anxiety, and SUD
interact and how they are associated.
Intriguingly, however, anxiety spectrum disorders were not
correlated to alexithymia levels in this research; thus, the current
results are in line with other authors, who assert that anxiety and
SUD are related independently of any anxiety disorder. That is,
anxiety may be present transversally, as a symptom or trait in
SUD (26, 52).
Closely connected to anxiety, depressive symptoms were
significantly associated with higher alexithymia levels in the
bivariate analysis. This finding was expected because alexithymia
is correlated with negative affects (16, 27, 29). It is important
to highlight that depression does not influence the stability
of alexithymia scores in SUD patients (16, 17). Anxiety and
depressive symptoms could partially explain the impaired
psychological item on the EuropASI, as both factors have been
correlated to this domain (26). Thus, in the current results, SUD
patients with higher alexithymia levels had more anxiety, more
depressive symptoms, and greater psychological impairments as
measured by the EuropASI.
Alexithymia and impulsivity imply several cognitive processes
and are key points, not only in emotional deregulation, but
also in SUD (18, 53). We found a positive relationship between
impulsivity and alexithymia in SUD patients, which could be
expected because impulsivity and SUD are closely related (1).
Previous studies support these results. For example, Shishido
et al. (53) have found that alcohol-dependent patients with high
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TABLE 2 | Substance use related variables analyzed by comparing to mean scores of alexithymia.
Lifetime history of substance use disorders % Mean score of TAS-20 ± SD t p
Alcohol use disorder Yes 62.8 57.54 ± 13.36 1.040 0.301
No 37.2 54.77 ± 10.86
Cannabis use disorder Yes 60.6 60.81 ± 12.98 2.710 <0.008*,**
No 39.4 53.72 ± 11.44
Cocaine use disorder Yes 61.7 57.09 ± 13.46 0.565 0.574
No 38.3 55.58 ± 10.89
Opioid use disorder Yes 21.3 58.70 ± 13.09 0.882 0.380
No 78.7 55.92 ± 12.36
Benzodiazepine use disorder Yes 19.2 60.94 ± 11.39 1.691 0.094
No 80.8 55.46 ± 12.59
Tobacco use disorder Yes 78.7 57.01 ± 12.32 0.749 0.456
No 21.3 54.65 ± 13.31
SUD severity according to EuropASI†
Medical ≤0.18 54.60 ± 13.66 2.051 <0.043*
>0.19 59.71 ± 12.43
Employment support status ≤0.56 55.61 ± 12.96 1.312 0.192
>0.57 58.92 ± 13.45
Alcohol ≤0.16 56.34 ± 12.30 0.621 0.536
>0.17 57.90 ± 14.27
Drugs ≤0.21 55.30 ± 11.85 1.541 0.126
>0.22 59.16 ± 14.51
Legal 0 58.41 ± 14.57 0.528 0.599
>0.1 56.74 ± 12.93
Socio-familiar ≤0.36 54.45 ± 13.15 2.333 <0.021*
>0.37 60.24 ± 12.73
Psychological ≤0.43 51.18 ± 10.71 5.289 <0.001*,**
>0.44 63.07 ± 12.90
†The sample was dichotomized by using median. Therefore, the percentage in each group is 50%.
*The result is statistically significant.
**The result is statistically significant after Bonferroni correction.
alexithymia levels act impulsively as a response to distressed
moods (53). Similarly, the relationship between impulsivity and
alexithymia has been described in patients with cannabis use
disorder and pathological gambling (18, 54).
Regarding the above, Thorberg et al. (38) state that loss
of control over drinking could mediate between alexithymia
and HRQoL (38). This point is important because we have
found a negative relationship between HRQoL and alexithymia
scores. This relationship between HRQoL impairments and
alexithymia in SUD patients has previously been described
(36, 38), and it could be analyzed in several ways. In the
current research, SUD patients with higher levels of alexithymia
also exhibited more psychiatric comorbidities, and it has
been stated that HRQoL perceptions could vary depending
on the presence of psychiatric comorbidities (2). Evren et al.
(36) also explain that difficulties in identifying feelings are
connected to HRQoL, and such difficulties could influence how
patients perceive their HRQoL (36). Additionally, negative affects
(anxiety and depression) correlate with worse PCS in HRQoL
among SUD patients (2). Interestingly, in this research, after
multivariate analysis, PCS was significantly connected to higher
levels of alexithymia in patients with SUD, and, in previous
studies, PCS has been related to difficulties with identifying
feelings (36).
Finally, although substance-induced psychosis was only
significantly related to higher levels of alexithymia in the bivariate
analysis, we consider it is important to analyze this correlation
since, as far as we know, this is the first time it is reported.
This finding could be related to studies in other populations,
which state that alexithymia may be a risk factor for psychotic
experiences (28, 34). Thus, it can be hypothesized that, in
the current case, substance use led to psychotic experiences in
patients with higher levels of alexithymia. Also, several points
frequently considered to be risk factors for substance-induced
psychosis were present in patients with higher alexithymia levels,
such as cannabis use disorder (35). Future studies should further
analyze this result, discriminating between the various substances
used, as some substances induce psychosis more frequently than
others (35).
Despite its intriguing and novel results, this study does present
some limitations. This research had a cross-sectional design, and,
therefore, the findings should be examined in longitudinal studies
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TABLE 3 | Current psychiatric comorbidity and psychological symptoms of patients, analyzed by alexithymia levels.
Variable Total % Mean score of TAS-20 ± SD t p
Psychiatric disorders†
Dual diagnosis Yes 63.7 60.14 ± 11.45 2.510 <0.017*
No 36.3 53.92 ± 12.85
Mood spectrum disorders Yes 41.7 61.18 ± 13.25 2.356 <0.021*
No 58.3 55.41 ± 11.46
Anxiety spectrum disorders Yes 27.3 60.53 ± 9.83 1.48 0.137
No 72.7 56.46 ± 13.60
Psychotic spectrum disorders Yes 21.1 62.96 ± 12.99 2.215 <0.034*
No 78.9 56.30 ± 12.06
Primary psychotic disorders Yes 13.9 60.53 ± 12.91 0.906 0.367
No 86.1 57.38 ± 12.46
Induced psychosis Yes 11.1 68.67 ± 11.18 3.457 <0.004*,**
No 88.9 56.71 ± 12.24
Attention deficit hyperactivity disorder Yes 8.4 62.13 ± 8.27 1.154 0.252
No 91.6 57.08 ± 12.08
Personality disorders†
Any personality disorder Yes 31.3 59.39 ± 13.91 1.126 0.263
No 68.7 56.37 ± 11.62
Cluster A personality disorders Yes 4.0 64.50 ± 18.43 1.159 0.249
No 96.0 57.17 ± 12.16
Cluster B personality disorders Yes 27.3 59.56 ± 14.33 1.104 0.272
No 73.7 56.47 ± 11.58
- Antisocial personality disorder Yes 20.0 63.15 ± 14.15 2.080 <0.048*
No 80.0 56.04 ± 11.61
- Borderline personality disorder Yes 10.1 62.00 ± 14.60 1.265 0.209
No 89.9 56.79 ± 12.10
- Narcissistic personality disorder Yes 4.0 47.75 ± 9.81 1.609 0.111
No 96.0 57.86 ± 12.39
Cluster C personality disorder Yes 4.0 60.50 ± 7.42 0.498 0.620
No 96 57.33 ± 12.59
Psychological traits/symptoms
BDI-I ≤18 52.7 51.94 ± 11.01 5.396 <0.001*,**
>19 47.3 64.66 ± 12.18
State anxiety (STAI)‡ ≤28 52.87 ± 11.87 3.970 <0.001*,**
>29 62.95 ± 11.93
Trait anxiety (STAI)‡ ≤33 51.82 ± 11.39 4.848 <0.001*,**,***
>34 63.51 ± 12.13
BIS-11 total score‡ ≤62 52.96 ± 11.89 3.957 <0.001*,**,***
>62 62.91 ± 12.33
Functional impulsivity (DII)‡ ≤32 56.48 ± 11.84 0.222 0.825
>33 57.11 ± 15.03
Dysfunctional impulsivity (DII)‡ ≤36 53.45 ± 12.07 2.691 <0.009*,**
>37 60.59 ± 13.38
HRQoL (SF-36)
Physical component summary HRQoL ≤50 64.6 60.52 ± 11.59 4.189 <0.001*,**,***
>51 35.4 50.29 ± 11.35
Mental component summary HRQoL ≤50 79.2 59.11 ± 11.86 3.539 <0.001*,**
>51 20.8 49.10 ± 11.08
†Other disorders were not analyzed due to small sample size (<5 patients per group).
‡The sample was dichotomized by using median. Therefore, the percentage in each group is 50%.
BDI-I, Beck Depression Inventory; BIS-11, Barratt Impulsivity Scale; DII, The Dickman Impulsivity Inventory; HRQoL, Health-related Quality of Life measured by the The Short-Form 36;
STAI, Stait-Trait Anxiety Inventory.
*The result is statistically significant.
**The result is statistically significant after Bonferroni correction.
***The result is statistically significant after multivariate analysis.
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to evaluate their bilateral association and relevance. Regarding
the TAS-20, some authors argue that, as it is a self-rated scale,
its results could be biased (9, 16). However, it is still considered
the gold standard instrument for evaluating alexithymia (9).
We did not individually analyze the three TAS-20 subfactors,
but such a sub-analysis could generate deeper conclusions.
Additionally, we used SCID-I and SCID-II for comorbidity
assessment. Despite SCID-I and SCID-II have demonstrated
their reliability and have hugely been used (and are still in
use) in modern research, those interviews use DSM-IV criteria
(55). Hence, the current findings should be analyzed taking
into account that some points are not comparable to the new
version of DSM. On the other hand, this research has provided
new insights concerning alexithymia in SUD. The study was
conducted in a clinical setting, and, hence, it presents information
for routine clinical practice in addiction treatment centers. To the
extent of our knowledge, some of the analysis presented here has
never been conducted before (especially among Spanish patients
with SUD).
According to the results described above, we conclude
that, in SUD patients, higher alexithymia levels are related to
psychiatric comorbidities (especially mood spectrum disorders
and substance-induced psychosis), increased levels of depression,
anxiety, and impulsivity, and worse HRQoL. Trait anxiety,
impulsivity, and PCS are the most important factors associated
with higher levels of alexithymia in SUD patients. Thus, it
is important to evaluate these factors in clinical practice and
provide accurate treatment programs including them.
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